Table 2. Summarized survival outcomes based on perioperative chemotherapy and cytoreduction (adapted from reference 24).

Variable	No. of studies	Mortality rate	Expected 1-year survival [%]	Expected 5-year survival [%]
Entire cohort	20	0.17 (0, 0.39)	84 [68–100]	42 [14–100]
EPIC used
Yes	7	0.16 (0, 0.44)	85 [64–100]	45 [11–100]
No	13	0.19 (0, 0.55)	83 [58–100]	39 [6–100]
Chemotherapy agents used
Mitomycin-C only	1	0.24	78	30
Cisplatin only	3	0.14	87	49
Doxorubicin + cisplatin	3	0.23	79	32
Docetaxel + cisplatin	1	0.35	70	17
Drug combinations including doxorubicin, mitomycin-C, cisplatin	11	0.16	85	45
Number of patients in a study
<100	17	0.20	82	37
>100	3	0.15	86	47
Median PCI score reported
<19	4	0.16	85	45
>19	16	0.17	84	42
Median no. of patients undergoing complete cytoreduction
<50%	6	0.18	84	41
≥50%	14	0.16	85	45

EPIC, early postoperative intraperitoneal chemotherapy; PCI, peritoneal cancer index.